Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation

Citizens initiated coverage of Immix Biopharma (NasdaqCM: IMMX) on March 9, 2026 with a Market Outperform rating and a price target implying 30.83% upside. The initiation is a positive sentiment catalyst that could support near-term share interest, though impact is likely limited absent company-specific news or material fundamental changes.

Analysis

Citizens initiated coverage of Immix Biopharma (NasdaqCM: IMMX) on March 9, 2026 with a Market Outperform rating and a price target implying 30.83% upside. The initiation is a positive sentiment catalyst that could support near-term share interest, though impact is likely limited absent company-specific news or material fundamental changes.